Veracyte to Release Fourth Quarter and Full-Year 2024 Financial Results on February 24, 2025
Veracyte (VCYT), a leading cancer diagnostics company, has announced it will release its Q4 and full-year 2024 financial results after market close on Monday, February 24, 2025. The company will host a conference call and webcast at 4:30 p.m. Eastern Time on the same day to discuss the results and provide a business update. The event will be accessible through a live webcast from the company's website, with dial-in registration available for the conference call. A webcast replay will be made available on the company's investor relations website following the broadcast.
Veracyte (VCYT), una delle aziende leader nella diagnostica oncologica, ha annunciato che rilascerà i suoi risultati finanziari del Q4 e dell'intero anno 2024 dopo la chiusura del mercato il lunedì 24 febbraio 2025. L'azienda organizzerà una teleconferenza e un webcast alle 16:30 ora orientale nello stesso giorno per discutere i risultati e fornire aggiornamenti aziendali. L'evento sarà accessibile tramite uno streaming dal vivo dal sito web dell'azienda, con registrazione telefonica disponibile per la teleconferenza. Una registrazione del webcast sarà resa disponibile sul sito web delle relazioni con gli investitori dell'azienda dopo la trasmissione.
Veracyte (VCYT), una empresa líder en diagnóstico de cáncer, ha anunciado que dará a conocer sus resultados financieros del cuarto trimestre y del año completo 2024 después del cierre del mercado el lunes 24 de febrero de 2025. La compañía llevará a cabo una conferencia telefónica y un webcast a las 4:30 p.m. hora del este el mismo día para discutir los resultados y proporcionar una actualización del negocio. El evento estará accesible a través de un webcast en vivo desde el sitio web de la empresa, con registro por teléfono disponible para la conferencia. Se hará disponible una repetición del webcast en el sitio web de relaciones con inversores de la empresa tras la transmisión.
Veracyte (VCYT)는 선도적인 암 진단 회사로, 2024년 4분기 및 전체 연도 재무 결과를 2025년 2월 24일 월요일 시장 종료 후 발표할 것이라고 발표했습니다. 회사는 동일한 날 동부 표준시 기준 오후 4시 30분에 결과를 논의하고 사업 업데이트를 제공하기 위한 컨퍼런스 콜 및 웹캐스트를 주최할 것입니다. 이 행사는 회사 웹사이트에서 실시간 웹캐스트를 통해 접근할 수 있으며, 전화 회의 등록도 가능합니다. 방송 이후에는 회사의 투자자 관계 웹사이트에서 웹캐스트 재방송이 제공될 예정입니다.
Veracyte (VCYT), une entreprise leader dans le diagnostic du cancer, a annoncé qu'elle publiera ses résultats financiers du quatrième trimestre et de l'année 2024 après la clôture des marchés le lundi 24 février 2025. L'entreprise organisera une conférence téléphonique et un webinaire à 16h30, heure de l'Est le même jour pour discuter des résultats et fournir une mise à jour sur l'entreprise. L'événement sera accessible via un webinaire en direct depuis le site web de l'entreprise, avec une inscription par téléphone disponible pour la conférence. Un enregistrement du webinaire sera proposé sur le site web des relations avec les investisseurs de l'entreprise après la diffusion.
Veracyte (VCYT), ein führendes Unternehmen im Bereich der Krebsdiagnostik, hat angekündigt, dass es seine Finanzergebnisse für das 4. Quartal und das gesamte Jahr 2024 nach Marktschluss am Montag, den 24. Februar 2025 veröffentlichen wird. Das Unternehmen wird am selben Tag um 16:30 Uhr Eastern Time eine Telefonkonferenz und ein Webcast veranstalten, um die Ergebnisse zu besprechen und ein Unternehmensupdate bereitzustellen. Die Veranstaltung wird über einen Live-Webcast auf der Unternehmenswebsite zugänglich sein, mit einer telefonischen Registrierung für die Konferenz. Eine Wiederholung des Webcasts wird nach der Übertragung auf der Investor Relations-Website des Unternehmens verfügbar gemacht.
- None.
- None.
The conference call will be webcast live from the company’s website and will be available via the following link: https://edge.media-server.com/mmc/p/8em9yd38. A webcast replay will be available following the conclusion of the live broadcast and will be accessible on the company’s website at https://investor.veracyte.com/events-presentations.
The conference call dial-ins can be accessed by registering at: https://register.vevent.com/register/BId0a04e7e33824346ad0b7e5eb4eb2525
About Veracyte
Veracyte (Nasdaq: VCYT) is a global diagnostics company whose vision is to transform cancer care for patients all over the world. We empower clinicians with the high-value insights they need to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. Our Veracyte Diagnostics Platform delivers high-performing cancer tests that are fueled by broad genomic and clinical data, deep bioinformatic and AI capabilities, and a powerful evidence-generation engine, which ultimately drives durable reimbursement and guideline inclusion for our tests, along with new insights to support continued innovation and pipeline development. For more information, please visit www.veracyte.com or follow us on LinkedIn or X (Twitter).
View source version on businesswire.com: https://www.businesswire.com/news/home/20250204129697/en/
Investors:
Shayla Gorman
investors@veracyte.com
(619) 393-1545
Media:
Tracy Morris
media@veracyte.com
(650) 380-4413
Source: Veracyte, Inc.
FAQ
When will Veracyte (VCYT) release Q4 and full-year 2024 earnings?
What time is Veracyte's (VCYT) Q4 2024 earnings call?
How can investors access Veracyte's (VCYT) Q4 2024 earnings call?
Will there be a replay available for Veracyte's (VCYT) Q4 2024 earnings call?
